Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-12 09:04 am Purchase | 2025-03-31 | 13G | Solid Biosciences Inc. SLDB | Adage Capital Management, L.P. | 6,729,484 8.680% | 4,975,325 (+283.63%) | Filing History |
| 2025-05-12 09:04 am Purchase | 2025-03-31 | 13G | Cidara Therapeutics, Inc. CDTX | Adage Capital Management, L.P. | 990,000 9.040% | 990,000 (New Position) | Filing History |
| 2025-05-12 09:03 am Purchase | 2025-03-31 | 13G | Ensysce Biosciences, Inc. ENSC | Adage Capital Management, L.P. | 74,711 5.320% | 74,711 (New Position) | Filing History |
| 2025-05-12 09:03 am Purchase | 2025-03-31 | 13G | Centessa Pharmaceuticals plc CNTA | Adage Capital Management, L.P. | 6,954,000 5.220% | 6,954,000 (New Position) | Filing History |
| 2025-05-12 09:02 am Purchase | 2025-03-31 | 13G | Traws Pharma, Inc. TRAW | Adage Capital Management, L.P. | 330,000 6.500% | 330,000 (New Position) | Filing History |
| 2025-05-12 09:02 am Sale | 2025-03-31 | 13G | UroGen Pharma Ltd. URGN | Adage Capital Management, L.P. | 1,277,000 2.770% | -1,651,086 (-56.39%) | Filing History |
| 2025-05-12 09:02 am Purchase | 2025-03-31 | 13G | Aeva Technologies, Inc. AEVA | Adage Capital Management, L.P. | 1,401,454 2.560% | 1,401,454 (New Position) | Filing History |
| 2025-05-12 09:01 am Sale | 2025-03-31 | 13G | Protara Therapeutics, Inc. TARA | Adage Capital Management, L.P. | 0 0.000% | -2,250,000 (Position Closed) | Filing History |
| 2025-05-12 09:01 am Purchase | 2025-03-31 | 13G | Mereo BioPharma Group plc MREO | Adage Capital Management, L.P. | 8,503,780 1.070% | 8,503,780 (New Position) | Filing History |
| 2025-05-12 09:00 am Sale | 2025-03-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Adage Capital Management, L.P. | 237,953 0.700% | -1,971,662 (-89.23%) | Filing History |
| 2025-05-12 09:00 am Purchase | 2025-03-31 | 13G | Abeona Therapeutics Inc. ABEO | Adage Capital Management, L.P. | 4,411,572 8.780% | 201,143 (+4.78%) | Filing History |
| 2025-02-12 09:46 am Purchase | 2024-12-31 | 13G | ProQR Therapeutics N.V. PRQR | Adage Capital Management, L.P. | 9,602,280 9.300% | 9,602,280 (New Position) | Filing History |
| 2025-02-12 09:45 am Purchase | 2024-12-31 | 13G | Monopar Therapeutics Inc. MNPR | Adage Capital Management, L.P. | 599,195 9.860% | 599,195 (New Position) | Filing History |
| 2025-02-12 09:44 am Sale | 2024-12-31 | 13G | Immunic, Inc. IMUX | Adage Capital Management, L.P. | 1,398,600 1.550% | -4,195,806 (-75.00%) | Filing History |
| 2025-02-12 09:36 am Purchase | 2024-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI | Adage Capital Management, L.P. | 436,737 5.180% | 436,737 (New Position) | Filing History |
| 2025-02-12 09:35 am Sale | 2024-12-31 | 13G | enGene Holdings Inc. ENGN | Adage Capital Management, L.P. | 1,528,768 3.000% | -801,000 (-34.38%) | Filing History |
| 2025-02-12 09:35 am Sale | 2024-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Adage Capital Management, L.P. | 2,209,615 6.680% | -388,121 (-14.94%) | Filing History |
| 2025-02-12 09:34 am Sale | 2024-12-31 | 13G | UroGen Pharma Ltd. URGN | Adage Capital Management, L.P. | 2,928,086 6.940% | -807,655 (-21.62%) | Filing History |
| 2025-02-12 09:33 am Purchase | 2024-12-31 | 13G | Dynamix Corporation Class A Ordinary Shares ETHM | Adage Capital Management, L.P. | 1,350,000 8.130% | 1,350,000 (New Position) | Filing History |
| 2025-02-12 09:33 am Purchase | 2024-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | Adage Capital Management, L.P. | 5,750,000 8.420% | 1,958,580 (+51.66%) | Filing History |